Advertisement
Advertisement
U.S. Markets open in 5 hrs
Advertisement
Advertisement
Advertisement
Advertisement

InVivo Therapeutics Holdings Corp. (NVIV)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.2000+0.0518 (+2.41%)
At close: 03:59PM EST
2.1900 -0.01 (-0.45%)
After hours: 07:59PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.1482
Open2.1600
Bid0.0000 x 1000
Ask0.0000 x 800
Day's Range2.0809 - 2.2000
52 Week Range1.9600 - 16.0000
Volume43,068
Avg. Volume221,257
Market Cap75.383M
Beta (5Y Monthly)1.11
PE Ratio (TTM)N/A
EPS (TTM)-1.3150
Earnings DateAug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    InVivo Therapeutics Announces Closing of $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules

    CAMBRIDGE, Mass, October 11, 2022--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has closed its previously announced registered direct offering for the sale and issuance of 154,000 shares of the Company’s common stock and pre-funded warrants to purchase up to 369,810 shares of common stock to a single healthcare-focused institutional investor. T

  • Business Wire

    InVivo Therapeutics Announces $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules

    CAMBRIDGE, Mass., October 07, 2022--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the sale and issuance of 523,810 shares of the Company’s common stock (or pre-funded warrants in lieu thereof), in a registered direct offering priced at-the-market

  • Business Wire

    InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright 24th Annual Global Investment Conference

    CAMBRIDGE, Mass., September 09, 2022--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming H.C. Wainwright 24th Annual Global Investment Conference, which runs from September 12 – 14, 2022. Dr. Toselli and company management will also be available to participate in

Advertisement
Advertisement